Allergan, Inc. (AGN) is a global specialty pharmaceutical company that develops and commercializes innovative products for the eye care, neuromodulator, skin care and other specialty markets.

Allergan has been expanding into new therapeutic areas through acquisitions over the past few quarters. We believe these acquisitions will provide the company with the opportunity to drive growth in its existing business and to expand into new areas of business. We are optimistic that Allergan’s presence across different segments and geographies should help maintain decent growth going forward even in the face of global economic weakness and foreign currency headwinds.

While growth will slow down in 2009 due to economic softness, company fundamentals remain strong. We believe Allergan is a good stock to own in the long run. As such, we maintain our Hold rating with a $42 price target.

Arpita Dutt contributed to this report.

Read the analyst note on AGN

“AGN” Free Stock Analysis: Buy? Sell? Hold?
Zacks Investment Research

Last 5 posts by Zacks Market Commentaries

• CNP & FPL Ink Pipeline Deal - Analyst Blog - November 20th, 2009
• Buffett Borrows for Rail Acquisition - Analyst Blog - November 20th, 2009
• Stone Energy Outdoes Estimates - Analyst Blog - November 20th, 2009
• Smucker's Beats, Raises Guidance - Analyst Blog - November 20th, 2009
• GameStop Meets Expectations - Analyst Blog - November 20th, 2009